Describe Guillain-Barré syndrome and its critical management.

• A. Acute ascending flaccid paralysis with hyporeflexia; monitor respiratory function; treat with IVIG or plasmapheresis
• B. Chronic autoimmune demyelination with cognitive impairment
• C. Central nervous system infection causing fever
• D. Progressive motor neuron degeneration without sensory loss

Answer: (A)

Guillain-Barré syndrome is an acute autoimmune neuropathy that presents with rapidly progressing, symmetric weakness that typically starts in the legs and ascends, with reduced or absent reflexes. The most critical management is preventing and addressing respiratory failure, since weakness can involve the diaphragm and breathing muscles. This means close respiratory monitoring with serial measurements of function (such as vital capacity and inspiratory force) and readiness to provide ventilatory support in the ICU if deterioration occurs. Early immune-directed therapy with intravenous immunoglobulin or plasmapheresis is used because both approaches help remove or neutralize the antibodies attacking peripheral nerves and can shorten the course and hasten recovery. Alongside this, supportive care is essential: monitor and stabilize autonomic function, manage pain, prevent venous thromboembolism, ensure adequate nutrition, and plan for rehabilitation. This picture is distinct from chronic autoimmune demyelinating diseases like multiple sclerosis, CNS infections, or motor neuron diseases like ALS, which do not involve this acute, ascending, hyporeflexic peripheral neuropathy or the same urgent need for respiratory-focused, ICU-level care with IVIG or plasmapheresis.